Continued Itacitinib Treatment for Myelofibrosis

Recruiting in Palo Alto (17 mi)

+25 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: Incyte Corporation

No Placebo Group

Prior Safety Data

Trial Summary

What is the purpose of this trial?This trial provides the medication itacitinib to participants from previous studies who may benefit from continued treatment. Itacitinib helps reduce inflammation by blocking specific proteins that cause it.

Eligibility Criteria

This trial is for patients already taking itacitinib in other Incyte-sponsored studies, who are benefiting and tolerating the treatment well. They must understand and agree to study procedures, avoid pregnancy or fathering children, and not have any illness that could risk their safety or study compliance.

Inclusion Criteria

Has demonstrated compliance, as assessed by the investigator, with the parent protocol requirements

Willingness to avoid pregnancy or fathering children

Ability to comprehend and willingness to sign an ICF

+4 more

Exclusion Criteria

Pregnant or breastfeeding women

Participants with an uncontrolled intercurrent illness or any concurrent condition that, in the investigator's opinion, would jeopardize the safety of the participant or compliance with the Protocol

I can get itacitinib through a pharmacy or my doctor.

Participant Groups

The trial provides ongoing access to itacitinib for participants from previous related studies. It's an open-label study where all involved know they're receiving itacitinib at doses and schedules set by earlier trials as long as benefits continue and side effects remain manageable.

1Treatment groups

Experimental Treatment

Group I: itacitinibExperimental Treatment1 Intervention

Participants will receive treatment with itacitinib as per the treatment dose and schedule they received in the study in which they were originally enrolled. Participants who are receiving ruxolitinib under parent protocol INCB39110-209 may continue to receive it as described in that protocol.